Mergers & Acquisitions ·
DataMeds AI completes acquisition of Helomics for $1.5 million in stock and convertible note
MEDSDataMeds AI, Inc.
On September 11, 2026, DataMeds AI, Inc. completed the acquisition of Helomics Corporation from Axe Compute Inc. for a total consideration valued at $1.5 million, consisting of 636,328 shares of common stock (approximately 19.99% of pre-transaction outstanding shares) and a convertible promissory note with a principal amount of $1,363,672.00. The note accrues interest at 7% per annum, matures on September 11, 2029, and converts to common stock at $1.00 per share upon stockholder approval. Helomics operates as a CLIA/CAP-certified AI cancer diagnostics laboratory and precision oncology CRO business. DataMeds AI, Inc. is a Health IT company that vertically integrates technology, pharmacy, pharmaceutical-adjacent services, and telemedicine to deliver healthcare experiences.